Skip to main content
Equibles
CRDF logo

CRDF · Cardiff Oncology, Inc. · Metrics

Track CRDF — free

Use CRDF with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

Claude ChatGPT Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$1.05 -0.06 (-5.00%)
Rebalance outlook locked
Going-concern doubt — flagged Aug 11, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Management has performed an analysis and concluded that there exists a substantial doubt about the Company's ability to continue as a going concern.”
View the 10-Q filed Aug 11, 2026
Market Cap
$85.57M
Shares
77.80M

CRDF metrics

64 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.10
Market cap
$85.57M

Price action

20 metrics
Price change (1W)
+16.0%
Price change (30D)
+5.8%
Price change (3M)
-27.3%
Price change (6M)
-42.0%
Price change (YTD)
-61.2%
Price change (1Y)
-48.8%
Trailing year
Price change (5Y)
-85.6%
52-week high
$3.21
52-week low
$0.81
Change from 52-week high
-66.0%
Change from 52-week low
+34.6%
Annualized volatility
84.2%
Annualized volatility (3M)
92.4%
Beta
2.1
RSI (14D)
60.1
Price vs SMA 50
+6.7%
Price vs SMA 200
-36.5%
Avg volume (3M)
1.26M
Relative volume
0.4
Average dollar volume
$1.37M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
77.80M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
166.9×
reciprocal yield 0.6%
P / book
3.2
reciprocal yield 31.3%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-47.2%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-06-03

Profitability

9 metrics
Gross margin
—
Operating margin
-8,320.1%
Trailing 12 months
Net margin
-7,884.1%
Gross profit (TTM)
—
Operating profit (TTM)
−$42.27M
Net income (TTM)
−$40.05M
Trailing 12 months
Diluted EPS (TTM)
$-0.60
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-0.39

Growth

11 metrics
Revenue growth YoY
-14.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$508,000
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+2.8%
Year over year · more shares
Revenue CAGR (3Y)
+15.4%
Revenue CAGR (5Y)
+10.1%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-151.0%
Return on assets
-107.3%
Debt / equity
—
Current ratio
3.3
EBITDA (TTM)
−$41.91M
Free cash flow (TTM)
—
Quick ratio
3.3
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$34.52M
Latest balance sheet
Cash & equivalents
$9.20M
Total assets
$37.33M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$40.85M
Capital expenditures (TTM)
$62,000
R&D (TTM)
$25.95M
SG&A (TTM)
$16.82M
Stock compensation (TTM)
$5.22M
R&D / revenue
5,108.7%
Stock compensation / revenue
1,028.5%

Ownership (13F)

3 metrics
13F filers
106
13F filer change QoQ
-11
Institutional ownership
24.4%

Short interest

3 metrics
Short interest
15.3%
Latest settlement · 15.3 days to cover
Days to cover
15.3d
Short-squeeze score
83 / 100

Insider activity

2 metrics
Net insider buying (90D)
$1.12M
Insider-sentiment score
93 / 100

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1213037 CUSIP 14147L108 13F (30d) 68 filings 68 filers Visit website Investor relations